BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » MD Anderson and NIH to Fund Clinical Trial Combining 2 Mesoblast Technologies
Mesoblast, NIH, MD Anderson

MD Anderson and NIH to Fund Clinical Trial Combining 2 Mesoblast Technologies

December 9, 2016 By Cade Hildreth (CEO) 1 Comment

On December 6th, MD Anderson Cancer Center and NIH announced that they will be funding a clinical trial that will combine two Mesoblast technologies:

Discover class-defining bioproduction tools.
  1. Mesenchymal Precursor Cell (MPC)-based expansion
  2. Ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients

The purpose of the trial is to provide clinical data to indicate whether these technologies can interact synergistically to promote faster cord blood HSC engraftment for bone marrow transplant patients.

Mesoblast Clinical Trial Evolution

Mesoblast Headquartered in Melbourne, Australia, Mesoblast Limited is a regenerative medicine company. It was founded by Silviu Itescu in 2004, and he remains at the helm of the company as CEO and Managing Director. Mesoblast is best known for its development of mesenchymal lineage cells, including mesenchymal precursor cells (MPCs) and mesenchymal stem cells (MSCs).

bitbio

To date, Mesoblast has had the Japanese government approve TEMCELL® HS. Inj, a product that it licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft vs host disease (GvHD).  In addition to launching the first allogeneic cell-based product to receive full regulatory approval in Japan, Mesoblast expects to launch the first industrially manufactured allogeneic cell-based product in the U.S., stating “Our product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with FDA discussions for children with steroid-refractory acute graft versus host disease.”

Mesoblast also has two other  lead product candidates, MPC-150-IM and MPC-06-ID, whic are in Phase 3 programs targeting advanced chronic heart failure and chronic low back pain.

Pluristyx

Now, the company is exploring its Mesenchymal Precursor Cell (MPC)-based expansion technologies in conjunction with the MD Anderson Cancer Center (MDACC) and the NIH.

As stated by Dr. Shpall of the MDACC, “Our data suggest that combining Mesoblast’s MPC-based HSC expansion and ex vivo fucosylation technologies may be the optimal clinical strategy for rapid engraftment of cord blood transplants, potentially making cord blood transplantation a real option for many desperate patients who cannot find a suitable alternative.”

To learn more, view the full Mesoblast announcement here.

Rate this post

Filed Under: MSCs, Stem Cell News Tagged With: cord blood, MD Anderson, Mesoblast, MSC, NIH

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. greg martin says

    December 10, 2016 at 11:47 am

    http://www.theglobeandmail.com/report-on-business/bayer-ag-investing-in-toronto-based-stem-cell-research-company/article33292430/

    Things are heating up again in the regenerative medicine space. Mesoblast is a long term play unless low back pain study pans out well. Capricor could be in a sweet spot with DMD success and passage of 21st Century Cures Act.

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.